RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제
      • 좁혀본 항목 보기순서

        • 원문유무
        • 원문제공처
        • 등재정보
        • 학술지명
        • 주제분류
        • 발행연도
        • 작성언어
        • 저자
          펼치기

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        한반도 南部 終末期 櫛文土器와 繩文土器의 年代的 병행관계 검토

        Okada Ken Ichi(岡田憲一),Ha In Soo(河仁秀) 한국신석기학회 2009 한국신석기연구 Vol.- No.17

        본고의 목적은 동삼동패총에서 출토된 繩文時代 後期土器를 검토 분석함으로써 한 반도 남부 지역 종말기 즐문토기와 승문토기의 연대적 병행관계를 파악하는데 있다. 검토 결과 동삼동패총에서 출토된 2점의 승문토기는 기존에 알려진 승문시대 후기 후엽의 南福寺式토기 등과는 그 형식과 시기를 달리하며, 지금까지 한반도 남해안지 역에서 발견된 승문토기 중 가장 늦은 승문 후기 중엽에서 후엽에 속하는 형식이다. 이것은 기존에 이중구연토기가 연대적으로 승문시대 후기 중엽으로 막연히 인식되어 왔던 사실을 이번 동삼동 출토 승문토기의 분석과 형식 검토를 통해 그 연대를 내 려볼 수 있게 되었음을 의미한다. 또 하나는, 동삼동패총에서 확인된 승문시대 후기 후반 토기가 일본 서북부 구주지 방이 아닌 동북부 구주지방과의 관련을 짐작해 볼 수 있다 점이다. 지금까지 한반도 에서 확인되는 승문시대 후기 전반까지의 토기 요소는 기본적으로 일본 구주의 서북 부 및 중부 구주지방과 관련성이 높은 것으로 추정되어 왔으며, 阿高式, 南福寺式, 사 까나시다식 토기형식이 이를 증명하고 있다. 하지만, 승문시대 후기 중엽 이후가 되면 일변하여 교류대상 지역이 동북부 구주지방으로 전환했을 가능성도 염두에 둘 필요가 있을 것으로 생각된다. 이러한 사실은 한반도 남부와 일본열도와의 교류가 한정된 지 역내에서 만 지속적으로 이루어 진 것이 아니고, 단속적이며 지역적인 관계가 유연하 였음을 반영하는 것으로 추정된다. The study aims to chronological parallel relationships between late chulmun pottery and jomon pottery in the southern Korean peninsula by reviewing and analyzing pottery excavated from Dongsam-dong shell mound in the jomon period. As the results of study, it shows that two pieces of jomon pottery excavated from Dongsam-dong shell mound have different types and times from the previously known late-nanpuguji type pottery in the late jomon period, and they are types involved in the middle-and-late type of the late jomon period, which is latest among jomon pottery which has been found until now in the southern Korean peninsula. In addition, this data can be a clue to analyze parallel relationships of late jomon pottery through the assemblage relations with chulmun pottery. The end of chulmun pottery in the southern Korean peninsula is related with the late mimanda type pottery stage compared to the chronology of jomon pottery in Japan. Through the finding, the fact, that pottery with double mouth rim has been vaguely considered as the middle-pottery of the late jomon period, was examined chronically through an analysis and type review of jomon pottery excavated in Dongsam-dong. On the other hand, the late-pottery, which is excavated from Dongsam-dong shell mound, in the late jomon period is expected to have the relations with Japan’s northeast Kyushu, not with northwest Kyushu. The pottery elements until the beginning of the late jomon pottery, which has been found in the southern Korean peninsula until now, seem to basically have high correlations with Japan’s northwest and central Kyushu, and adagga type pottery, nanpuguji type pottery, and sagganasida type pottery prove this. However, it needs to consider that interchange areas may transfer to the northeast Kyushu by changing completely from the middle of the late jomon period. Based on the fact, it is estimated to reflect that the interchange between the southern Korean peninsula and Japan was not made only in the designated area continuously, and that intermittent and regional relations were flexible.

      • The Impact of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

        ( Manabu Kawai ),( Seiko Hirono ),( Ken-ichi Okada ),( Motoki Miyazawa ),( Yuji Kitahata ),( Ryohei Kobayashi ),( Masaki Ueno ),( Shinya Hayami ),( Hiroki Yamaue ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1

        Backgrounds: According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, pancreatic ductal adenocarcinoma (PDAC) can be classified as resectable, borderline resectable, or unresectable. Although borderline resectable PDAC (BRPC) may technically be resectable, it has particularly high risks of margin-positive resection and postoperative recurrence. Therefore, preoperative treatment is recommended for BRPC patients in both the NCCN Guidelines and an expert consensus statement. However, the establishment of the most appropriate neoadjuvant therapy is needed by further studies. The aim of these studies is to evaluate the impact of neoadjuvant chemotherapy for BRPC and confirm the safety and efficacy of two regimens of neoadjuvant therapy for BRPC. Our Clinical Trials: First, we evaluated the impact of neoadjuvant chemotherapy for BRPC. 143 BRPC-A patients undergoing pancreatectomy were reviewed from among 330 pancreatic cancer patients, including 111 potentially resectable pancreatic cancer patients and 76 BRPC with portal vein involvement patients. We compared the clinicopathological factors of 40 BRPC-A patients treated with neoadjuvant treatment followed by surgery and those of 103 BRPC-A patients treated with upfront surgery. The R0 rate and progression-free survival of BRPC-A patients who received neoadjuvant therapy and subsequent surgical resection were significantly better compared to those who received upfront surgery (R0: P = 0.041; progression-free survival: P = 0.033), but overall survival was not significantly different. Neoadjuvant treatment followed by surgery might provide clinical benefits for BRPC-A patients; however, the establishment of the most appropriate neoadjuvant treatment is needed by further studies. To evaluate appropriate neoadjuvant treatment, two prospective pilot trials were conducted as follows; modified FOLFIRINOX (without bolus 5-FU and LV, also decreased the dose of irinotecan; FIRINOX) and nab-paclitaxel plus gemcitabine therapy. Modified FOLFIRINOX was given to the first five patients in the 4-cycle group of the regimen and next five patients in the 8-cycle group. The primary end point was the toxicity of the therapy and one of the secondary end points were the optimal duration. The overall rate of grade 3 and 4 events was 80 %: 3 patients (60%) in the four-cycle group and five patients (100%) in the eight-cycle group had grade 3 or 4 adverse events. There was no incidence of serious adverse effect such as febrile neutropenia, sepsis, liver abscess or uncontrollable diarrhea. There was no clinically relevant morbidity presented in patients who underwent surgery. R0 rates by intention to treat were 60.0% in the four-cycle group and 40 % in the eight-cycle group (P = 0.999). The histopathologic treatment effect based on the Evans grade revealed grade I (n = 1), IIa (n = 3) in the four-cycle group and grade I (n = 2), IIa (n = 1) in the eight-cycle group. Nab-paclitaxel plus gemcitabine therapy: the primary endpoint was the toxicity, and secondary endpoints were the resection rate, the R0 resection rate. The overall rate of any grade and grade 3-4 events were 100% and 90%. The majority of these adverse events represented expected neutropenia. The resection and R0 resection rates were 80% and 70%, respectively. Conclusion: FIRINOX therapy was feasible and safe for strictly selected patients with BRPC. On the other hand, nab-paclitaxel plus gemcitabine therapy was safe and feasible without strict selection of patients with BRPC. A multicenter phase II study is in progress to investigate the efficacy of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival (UMIN000024154).

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼